Eli Lilly's drug cuts COVID-19 recovery time in remdesivir-combo study

science

science / science 15 Views comments

Eli Lilly's drug cuts COVID-19 recovery time in remdesivir-combo studyThe drug baricitinib, branded as Olumiant, cut the median recovery time by about a day when added to remdesivir, compared to patients treated with the antiviral alone, Lilly said. Remdesivir was granted an emergency use authorization (EUA) in May after trial data showed it helped shorten hospital recovery time by 31%. Lilly said it plans to discuss the potential for an EAU for baricitinib with the U.S. Food and Drug Administration, based on the results from the trial, which tested more than 1,000 patients.


Comments